Voluntary announcement phase iii clinical study results of oturkibart (qx005n) for treatment of prurigo nodularis presented as a late-breaking oral presentation at eadv 2026
Filed with HKEX · Stock code 2509 ·
6ix hasn’t read this filing yet.
View original source (HKEXnews)Company analysis